Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.71 |
| ▸ | CNR2 | P34972 | 4/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715812 | 0.89 | CNR1 (0.57) | CNR1CNR2AGTR1 | |
| SCHEMBL4714742 | 0.89 | CNR1 (0.61) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL4715384 | 0.89 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL763014 | 0.83 | CNR1 (1.00) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL4715388 | 0.83 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL4711663 | 0.82 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL4712910 | 0.79 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL4711462 | 0.78 | CNR1 (0.72) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL4711661 | 0.78 | CNR1 (0.71) | CNR1CNR2 | |
| SCHEMBL8427702 | 0.78 | CNR1 (0.49) | CNR1CNR2ADRB2ADRA2AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214856-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | claimed |
| EP-1622903-B1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PROD INC (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1622903-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094421-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214856-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214856-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885ADRB2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.